MX2012010148A - Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion. - Google Patents

Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.

Info

Publication number
MX2012010148A
MX2012010148A MX2012010148A MX2012010148A MX2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A
Authority
MX
Mexico
Prior art keywords
denaturing
soluble recombinant
recombinant interferon
interferon protein
producing soluble
Prior art date
Application number
MX2012010148A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey Allen
Ping-Hua Feng
Anant Patkar
Keith L Haney
Lawrence Chew
Lei Lei Phokham Sengchanthalangsy
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of MX2012010148A publication Critical patent/MX2012010148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2012010148A 2010-03-04 2011-03-02 Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion. MX2012010148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31067110P 2010-03-04 2010-03-04
PCT/US2011/026921 WO2011109556A2 (en) 2010-03-04 2011-03-02 Method for producing soluble recombinant interferon protein without denaturing

Publications (1)

Publication Number Publication Date
MX2012010148A true MX2012010148A (es) 2013-01-22

Family

ID=44531690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010148A MX2012010148A (es) 2010-03-04 2011-03-02 Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.

Country Status (16)

Country Link
US (2) US9187543B2 (enExample)
EP (1) EP2542574B1 (enExample)
JP (1) JP5840148B2 (enExample)
KR (1) KR101857825B1 (enExample)
CN (1) CN102906108B (enExample)
AU (1) AU2011223627B2 (enExample)
BR (1) BR112012022292A2 (enExample)
CA (1) CA2791361C (enExample)
CL (1) CL2012002378A1 (enExample)
CO (1) CO6592086A2 (enExample)
ES (1) ES2639398T3 (enExample)
MX (1) MX2012010148A (enExample)
NZ (1) NZ602255A (enExample)
PE (1) PE20130557A1 (enExample)
RU (1) RU2573909C2 (enExample)
WO (1) WO2011109556A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104151420A (zh) * 2013-05-15 2014-11-19 复旦大学 长效干扰素及其制备方法和用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN107099569B (zh) * 2017-06-30 2021-05-07 北京生物制品研究所有限责任公司 一种规模化发酵生产重组人干扰素β1b蛋白的方法
EP4161943A4 (en) * 2020-06-09 2025-01-01 Icosavax, Inc. Method of making virus-like particle
CN116120424A (zh) * 2022-06-06 2023-05-16 江苏靶标生物医药研究所有限公司 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US5702699A (en) * 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) * 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695455A (en) * 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) * 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5128130A (en) * 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) * 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5169760A (en) * 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1992006116A1 (en) 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5508192A (en) * 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5240834A (en) * 1991-01-22 1993-08-31 Albert Einstein College Of Medicine Of Yeshiva University Solubilization of protein after bacterial expression using sarkosyl
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ITFI940106A1 (it) 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
RU2098124C1 (ru) * 1994-10-24 1997-12-10 Общество с ограниченной ответственностью "Ниготек" Способ получения интерферона
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
CA2309766C (en) * 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
CZ292475B6 (cs) 1999-02-18 2003-09-17 Rmf Dictagene S.A. Vakcína proti malárii a polypeptid
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
KR100358948B1 (ko) 2000-03-31 2002-10-31 한국과학기술원 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균
CA2421760A1 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
EP1343518B1 (en) * 2000-11-07 2009-07-22 Novartis Vaccines and Diagnostics, Inc. Stabilized interferon compositions
BR0207020A (pt) 2001-02-06 2004-06-22 Merck Patent Ges Mit Beschaenk Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida
CA2438628A1 (en) 2001-02-19 2002-08-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Artificial proteins with reduced immunogenicity
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
AU2002330091A1 (en) 2001-09-10 2003-03-24 Emd Biosciences, Inc. Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first
US20040247562A1 (en) 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
JP4326470B2 (ja) 2002-08-31 2009-09-09 シージェイチェイルジェダンコーポレーション 糖鎖化ヒト顆粒球コロニー刺激因子同種体
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8399217B2 (en) * 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
US20050186666A1 (en) * 2003-11-19 2005-08-25 Dow Global Technologies Inc. Protein expression systems
BRPI0416807A (pt) * 2003-11-21 2007-01-09 Dow Global Technologies Inc sistemas de expressão aperfeiçoados com secreção de sistema sec
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
BRPI0506917A (pt) 2004-01-16 2007-06-05 Dow Global Technologies Inc expressão de proteìnas de mamìferos em pseudomonas fluorescens
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
ATE501168T1 (de) * 2004-12-20 2011-03-15 Cadila Healthcare Ltd Verfahren zur herstellung von hohen niveaus von interferon-beta
EP1828241A1 (en) * 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
GB0605684D0 (en) 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
MX2008015213A (es) * 2006-05-30 2008-12-09 Dow Global Technologies Inc Metodo de optimizacion de codon.
EP1939212A1 (en) 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds
CN102517280A (zh) * 2007-01-31 2012-06-27 菲尼克斯股份有限公司 用于提高表达的细菌前导序列
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009023270A2 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
NZ603033A (en) * 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell

Also Published As

Publication number Publication date
PE20130557A1 (es) 2013-05-19
KR20130018743A (ko) 2013-02-25
JP5840148B2 (ja) 2016-01-06
WO2011109556A2 (en) 2011-09-09
WO2011109556A3 (en) 2012-01-12
US9187543B2 (en) 2015-11-17
AU2011223627B2 (en) 2015-06-18
CA2791361A1 (en) 2011-09-09
US20160032345A1 (en) 2016-02-04
US9611499B2 (en) 2017-04-04
RU2573909C2 (ru) 2016-01-27
CN102906108B (zh) 2016-01-20
JP2013524775A (ja) 2013-06-20
NZ602255A (en) 2014-04-30
CO6592086A2 (es) 2013-01-02
EP2542574A4 (en) 2014-01-29
BR112012022292A2 (pt) 2017-01-10
KR101857825B1 (ko) 2018-05-14
CA2791361C (en) 2018-06-12
EP2542574B1 (en) 2017-08-09
RU2012141653A (ru) 2014-04-10
CN102906108A (zh) 2013-01-30
US20110217784A1 (en) 2011-09-08
AU2011223627A1 (en) 2012-09-27
ES2639398T3 (es) 2017-10-26
EP2542574A2 (en) 2013-01-09
CL2012002378A1 (es) 2014-01-10

Similar Documents

Publication Publication Date Title
EP2542574A4 (en) METHOD FOR PRODUCING A SOLUBLE AND RECOMBINANT INTERFERON PROTEIN WITHOUT DENATURING
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
HK1206761A1 (en) Nutritive fragments, proteins and methods
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
WO2014028453A3 (en) Natural killer cells and uses thereof
HK1214739A1 (zh) 工程化的分泌蛋白质和方法
MX348071B (es) Variantes de fc.
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
EP2470670A4 (en) COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
MX2015016380A (es) Produccion de productos de la proteina de leguminosa con astringencia reducida.
CY1118856T1 (el) Εμβολιο pcsk9
MX2017000014A (es) Metodo para producir acido graso de cadena media con el uso de beta-cetoacil-proteina portadora de acilo (acp) sintasa.
MX364623B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
MY180953A (en) Acyl-acp thioesterase
NZ590143A (en) Anti-inflammatory proteins and methods of preparation and use thereof
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
IN2015DN03206A (enExample)
WO2014122161A3 (en) Use of polypeptides having protease activity in animal feed
PH12012502188B1 (en) Thioesterase and method for producing fatty acid or lipid using same
WO2018132821A3 (en) Elastomeric proteins
NZ596501A (en) Casb7439 constructs
MY182519A (en) Method for producing lipid using acyl-acp thioesterase
WO2011123570A3 (en) Methods for g-csf production in a pseudomonas host cell
WO2015143512A3 (en) Enhancement of recombinant protein expression with copper